Muscular dystrophies are a heterogenous group of inherited muscular disorders characterized by progressive muscle weakness. Historically, these disorders are difficult to treat. In the last three decades, there is a great progress in molecular and genetic basis of these disorders; early diagnosis is achievable with proper clinical recognition and advanced genetic testing .Duchenne Muscular Dystrophy (DMD) is a neuromuscular muscular X-linked recessive disorders that belong to a group of disorders known as dystrophinopathies. DMD characterized by a progressive degeneration of skeletal muscles, with symptoms that manifest early, at around 3 years, causing loss of ambulation within the 13 years of life, followed by cardiac complication (e.g., dilated cardiomyopathy and arrhythmia) and respiratory disorders, including chronic respiratory failure. The unique medical treatment available is steroid therapy, which appears to prolong walking capacity by at least two years. Thus, besides medical treatment, the physical therapy in multidisciplinary care is imperative for alleviating muscle atrophy, skeletal deformities, and motor function deterioration.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Enrollment
50
MLPA test for genetic testing to detect gene affection in DMD , and other tests for confirmation and follow up
Sohag University Hospital
Sohag, Egypt
change in dystrophine gene mutation
MLPA test
Time frame: within six months
change in MRI findings in DMX patient from normal
by MRI brain
Time frame: within six months
change in cardiac function in DMD patient
by Echocardiography to detect EF, FS
Time frame: within six months
change in thyroid function in DMD patient
by thyroid function test
Time frame: within six months
change in cognitive function in DMD patients
by Stanford IQ test
Time frame: within six months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.